At Bantam Pharmaceutical, we are developing novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors.
Our mission is to destroy cancer cells from the inside, using our unique expertise to alter their inner mitochondrial dynamics.
Our lead candidate is BTM-3566, an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL).
We are leveraging our science across two workstreams:
BTM-3566: We are progressing our lead candidate into the clinic
Discovery: We are uncovering other potential small molecules with applications in oncology
Our strategy will enable us to develop a pipeline of future indications in selected solid and hematological tumors, opening the door to new compounds and patient populations experiencing severe unmet need.